インデックス付き
  • Jゲートを開く
  • アカデミックキー
  • 研究聖書
  • 中国国家知識基盤 (CNKI)
  • 国際農業生物科学センター (CABI)
  • レフシーク
  • ハムダード大学
  • エブスコ アリゾナ州
  • OCLC-WorldCat
  • CABI全文
  • パブロン
  • ジュネーブ医学教育研究財団
  • Google スカラー
このページをシェアする
ジャーナルチラシ
Flyer image

概要

Favipiravir: Promising Therapy for COVID-19

Amit Kumar Das*

COVID 19 is become one of the most threatened pandemics in recent time and spreading rapidly. Favipiravir, an antiviral drug, has shown promising but yet unproven effect against COVID-19 infection. Drug Controller General of India (DCGI) has recently approved Favipiravir for treating moderate to severe COVID-19 infected patients. Favipiravir, a broad-spectrum antiviral drug that interferes with the viral replication and emerging as promising therapeutic potential as indicated by initial clinical studies. In this literature review author tries to summaries an overview of Favipiravir as a promising therapy for COVID-19 disease.